Predictive factors associated with immunosuppressive agent use in ulcerative colitis: A case-control study

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 5, 2008, Pages 606-613

  Lau, A ^a,b   Chande, N ^b   Ponich, T ^b   Gregor, J C ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; STEROID;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL FEATURE; COLITIS; CONTROLLED STUDY; DIARRHEA; DIGESTIVE TRACT ENDOSCOPY; DISEASE SEVERITY; EPIDEMIC; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOCHEZIA; HOSPITALIZATION; HUMAN; INTESTINE MOTILITY; LEUKOPENIA; LOGISTIC REGRESSION ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; STEROID THERAPY; SYSTEMIC THERAPY; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNIVARIATE ANALYSIS; VOMITING;

6-MERCAPTOPURINE; ADULT; ANTIMETABOLITES; AZATHIOPRINE; CASE-CONTROL STUDIES; CHRONIC DISEASE; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME;

EID: 48449099921     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03772.x     Document Type: Article

References (44)

1. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Part I and II: short term and long-term prognosis. Gut 1963 4 : 299 315.
2. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci 1993 38 : 1137 46.
3. Faubion WA Jr., Loftus EV Jr., Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001 121 : 255 60.
4. Kornbluth A, Sachar D. Ulcerative Colitis Practice Guidelines in adults (Update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004 99 : 1371 85.
5. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute Technical Review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006 130 : 940 87.
6. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005 1 : CD004277.
7. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353 : 2462 76.
8. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005 128 : 1805 11.
9. Timmer A, McDonald JWD, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007 1 : CD000478.
10. Ardizzone S, Molteni P, Imbesi V, et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997 25 : 330 3.
11. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974 1 : 1067 70.
12. Caprilli R, Carratu R, Babbini M. Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary report. Am J Dig Dis 1975 20 : 115 20.
13. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992 305 : 20 2.
14. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004 99 : 1122 8.
15. Sood A, Midha V, Sood N, et al. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000 19 : 14 6.
16. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006 55 : 47 53.
17. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004 2 : 731 43.
18. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000 118 : 1025 30.
19. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980 43 : 651 62.
20. Package Insert for Azathioprine/6-Mercaptopurine. San Diego, California : Imuran®, Prometheus Laboratories, Inc., 2005.
21. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005 20 : 1149 57.
22. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in practicalities. Br Med J 1964 1 : 89 92.
23. Present DH, Meltzer SJ, Krumholz MP, et al. 6-mercaptopurine in the management of inflammatory bowel disease: short and long term toxicity. Ann Intern Med 1989 111 : 641 9.
24. Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006 12 : 543 50.
25. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007 132 : 507 15.
26. Kuriyama M, Kato J, Fujimoto T, et al. Risk factors and indications for colectomy in ulcerative colitis patients are different according to patient's clinical background. Dis Colon Rectum 2006 49 : 1307 15.
27. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007 5 : 103 10.
28. Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticoid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998 10 : 831 5.
29. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996 38 : 905 10.
30. Oshitani N, Kitano A, Fukushima R, et al. Predictive factors of the response of ulcerative colitis patients during the acute-phase treatment. Digestion 1990 46 : 107 13.
31. Chakravarty BJ. Predictors and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol 1993 88 : 852 5.
32. Seo M, Okada M, Yao T, et al. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol 2002 37 : 29 34.
33. Benazzato L, D'Inca R, Grigoletto F, et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 2004 36 : 461 6.
34. Meyers S, Lerer PK, Feuer EJ, et al. Predicting the outcome of corticoid therapy for acute ulcerative colitis: results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987 9 : 50 4.
35. Kumar S, Ghoshal UC, Aggarwal R, et al. Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol 2004 19 : 1247 52.
36. Carbonnel F, Gargouri D, Lemann M, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000 14 : 273 9.
37. Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004 19 : 1079 87.
38. Oshitani N, Matsumoto T, Jinno Y, et al. Prediction of short-term outcome for patients with active ulcerative colitis. Dig Dis Sci 2000 45 : 982 6.
39. Health Canada. Remicade (Infliximab) Advisory. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2006/ remicade_3_hpc-cps-eng.php (accessed 5 January 2007).
40. Navarro JT, Ribera JM, Mate JL, et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003 44 : 531 3.
41. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005 54 : 1121 5.
42. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001 121 : 1080 7.
43. Masunaga Y, Ohno K, Ogawa R, et al. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 2007 41 : 21 8.
44. Fraser AG, Ochard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002 16 : 1225 32.